Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alfacell Corporation has signed an agreement to allow the Novartis Institute for Tropical Diseases to test its anti-viral drug, AC 03-636, against dengue fever.
Subscribe to our email newsletter
Dengue fever is a mosquito-borne viral infection, causing fever and severe joint pain, hemorrhage and shock in some cases and, in the most severe cases, death. The World Health Organization estimates that 50 million cases occur each year, requiring 500,000 hospitalizations.
Alfacell will also provide technical assistance for all studies to be conducted by NITD, based in Singapore.
“NITD is a global center of excellence in the area of Dengue fever research, possessing exceptional scientific resources and capabilities,” commented Andrew Aromando, senior vice president of commercial development at Alfacell. “Their commitment to reducing the incidence of deadly infectious diseases that affect millions in developing countries is unmatched. As such, NITD is extremely well-suited to conduct further research on AC 03-636.”